Trials / Not Yet Recruiting
Not Yet RecruitingNCT06671340
Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes
Effects of Repeated Dose of Dorzagliatin on Insulin Secretion, Glucagon Release and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Elaine Chow · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A total of 30 subjects will be recruited 15 with intermediate hyperglycemia and 15 in the tyep 2 diabetes group respectively. Eligible participants will undergo hyperglycemic-clamp/oral glucose tolerance at baseline and after 4 weeks of dorzagliatin treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dorzagliatin | chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral) |
Timeline
- Start date
- 2025-04-02
- Primary completion
- 2025-12-30
- Completion
- 2026-01-31
- First posted
- 2024-11-04
- Last updated
- 2025-03-04
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT06671340. Inclusion in this directory is not an endorsement.